Explore selected press coverage and media perspectives on Kenko Imalytics and the growing role of quantitative MRI in cancer care. From AI-enabled breast cancer detection to imaging biomarkers that support more objective tumour characterisation, these articles reflect the wider conversation around how advanced medical imaging can help radiologists make faster, more precise and more personalised clinical decisions.
Kenko applies MRI-based biomarkers to improve early breast cancer diagnosis, enabling faster interpretation and more informed clinical decision-making by radiologists.
AI applied to MRI enables improved oncological diagnosis by extracting quantitative biomarkers, supporting earlier detection, tumour characterisation, and clinical decision-making.
The shift from visual MRI interpretation to quantitative biomarkers enables a deeper understanding of tumour biology, improving diagnostic precision and supporting more objective clinical decision-making.
MRI-based biomarkers enable identification of breast tumour aggressiveness, linking imaging patterns to biological behaviour and supporting more precise diagnostic and treatment decisions.
MRI-based biomarkers enable non-invasive assessment of breast tumour aggressiveness, linking perfusion and diffusion patterns to biological behaviour and treatment decisions.
Breast cancer screening evolves towards personalised approaches integrating advanced imaging and AI, improving early detection, risk stratification, and diagnostic precision.
DNA repair signatures enable personalised cancer treatment by linking mutational patterns to underlying repair mechanisms, informing therapeutic strategies and overcoming resistance.
AI-driven MRI biomarkers enable earlier breast cancer detection, accelerating radiological workflows while revealing tumour behaviour through quantitative cellular and vascular patterns.
Kenko applies MRI-based biomarkers to breast cancer, enabling faster and more objective tumour characterisation through quantitative physiological insight.
Your login details have been sent to the email address linked to your authorised account. Please
follow the instructions included in that email to
access the platform securely.
Thank you.